Lilly, Genentech: Study in Rare Form of Alzheimer's Misses Main Endpoint
February 10 2020 - 6:45AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. (LLY) and Roche Holdings AG's (ROG.EB)
Genentech unit Monday said a phase 2/3 study of their
investigational therapies for Alzheimer's disease missed its
primary endpoint in people with a rare, early-onset, inherited form
of the disease.
The drug makers said the study, sponsored by Washington
University School of Medicine in St. Louis, didn't show a
significant slowing of the rate of cognitive decline in people
treated with Lilly's solanezumab and Roche's gantenerumab compared
with placebo in autosomal dominant Alzheimer's, which accounts for
less than 1% of all cases of the disease.
Genentech said it continues to study gantenerumab, a late-stage
investigational medicine, in a pair of large global phase III
studies in the broader population of people with Alzheimer's
disease that isn't directly caused by gene mutations.
Eli Lilly said it won't pursue a regulatory submission for
solanezumab in autosomal dominant Alzheimer's disease, but it said
the study's outcome doesn't affect an ongoing clinical trial
testing solanezumab in older individuals who have evidence of
amyloid in their brains but don't show symptoms of memory
impairment.
The companies said they are conducting further analyses of the
study, including secondary endpoints and biomarkers, in
collaboration with Washington University.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 10, 2020 06:30 ET (11:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024